R
Raghav Sundar
Researcher at National University of Singapore
Publications - 137
Citations - 2354
Raghav Sundar is an academic researcher from National University of Singapore. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 88 publications receiving 1392 citations. Previous affiliations of Raghav Sundar include University Health System & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Biomarkers for Homologous Recombination Deficiency in Cancer.
TL;DR: The biology and clinical validation of current methods to measure HRD are summarized to aid decision-making for patient stratification and translational research in PARP inhibitor trials, and newer assays undergoing clinical validation are examined.
Journal ArticleDOI
Nivolumab in NSCLC: latest evidence and clinical potential
TL;DR: Results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of the immune checkpoint modulator in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC are discussed.
Journal ArticleDOI
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
TL;DR: In this paper, the authors discuss the emerging data of how DNA damaging agents can enhance the immunogenic properties of malignant cells, focussing especially on immunogenic cell death, and the expansion of neoantigen repertoires.
Journal ArticleDOI
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Alex Molassiotis,Hui Lin Cheng,Violeta Lopez,Joseph S. K. Au,Alexandre Chan,Aishwarya Bandla,Kwun To Leung,Yu Chung Li,Kwan H. Wong,Lorna K.P. Suen,Choi Wan Chan,Janelle Yorke,Carole Farrell,Raghav Sundar +13 more
TL;DR: The historical variation reported in CIPN incidence and prevalence is possibly confounded by disagreement between assessment modalities, and clinical practice should consider assessment of motor neuropathy for neurotoxic chemotherapy.
Journal ArticleDOI
Immunotherapy in the treatment of non-small cell lung cancer
TL;DR: An overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection is provided.